Novavax Awarded $179M Contract by U.S. Govt. to Develop Flu Vaccines

During a 3-year base period valued at $97 million, Novavax will continue to develop its novel, clinical-stage influenza vaccines to address the Office Biomedical Advanced Research and Develop Authority’s commitment to pandemic preparedness. 
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.